

**Minutes of the HSE Directorate Meeting
held on
Wednesday 22nd February, 2017**

Directorate Members Present: T. O'Brien (Chairman), A. O'Connor, S. O'Keeffe, J. Hennessy, P. Healy, L. Woods and P. Crowley

Apologies: S. Mulvany

In attendance: D. Purcell (Secretary)

Joined the Meeting: None

Time & Location: Director General's Meeting Room (Room 1.11), Dr. Steevens' Hospital, Dublin 8 at 10.30am

Item	Discussion / Comments	Action
1	Correspondence from DoH regarding the drug Orkambi	
	<p>The correspondence from the DoH dated 21st February 2017 circulated prior to the meeting arising from consideration by the Leadership Team of the reimbursement of the drug Orkambi on the 14th February 2017 was reviewed and discussed in detail.</p> <p>The Minister requested the HSE Leadership Team further consider the reimbursement of Orkambi, having particular regard to both the Executive's statutory obligations and the potential to bring funding issues to the DoH for consideration.</p> <p><u>Action agreed:</u></p> <ul style="list-style-type: none"> • Following a wide-ranging discussion which reflected the complexity of the issues involved and taking account of the HSE's obligations under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE Directorate agreed to support the application for reimbursement under the revised terms now offered by Vertex, but only on the basis that additional funding to cover the costs involved is provided, and which is not available for the other health service priorities outlined in estimates submissions. • J. Hennessy to write to the DoH under the provisions of Clause 12 of the IPHA agreement informing them that the medicine is not affordable within existing resources, as this particular application has always been regarded as exceptional and outside of the scope of the existing Service Plan. 	J. Hennessy
2	Any Other Business	
	No matters were raised under this item	

The meeting concluded at 11.30am

Signed:

Date:

Tony O'Brien
Chairman
